We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Amar Vennapusa, a bariatric surgeon, fills a syringe with Eli Lilly's Mounjaro, a tirzepatide injection drug used for ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...